This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The U.S. Securities and Exchange Commission Monday laid out a proposal that would require businesses to disclose the emissions they produce. Kathleen Rogers, CEO & President at EARTHDAY.ORG, joined Cheddar News to break down the implications of this historic step.
Deepwell Digital Therapeutics is a game development company looking to transform the way we look at video games — this time to improve health outcomes. Its goal is to create software to aid those who deal with conditions such as depression and ADHD. Company co-founder and co-CEO Ryan Douglas and co-founder Kate Edwards joined Cheddar News to talk about the technology is being used to help patients. "From a research perspective, the game industry itself has been well aware for many, many years of the kind of inherent, kind of anecdotal therapeutic value of playing games," said Edwards.
Catching you up on what you Need to Know on Mar 21, 2022, with updates on the Russian invasion in Ukraine, a Boeing 737-800 plane carrying 132 people crashed in China, Canadian Pacific rail workers on strike, another possible COVID surge, and the SEC's new climate rules for businesses.
The Bill Gates-founded Breakthrough Energy company invested $80 million in Verdox Inc. to facilitate efficient, lower-cost technolog to remove carbon from the air and emission sources. CEO of Verdox, Brian Baynes, joined Cheddar News to discuss the investment, how the company's tech works, and where he sees it going. "We anticipate that with technologies like ours, we potentially can get to the scale of about a million tons per year within 5-10 years," he said. "And then ultimately we need to be doing this at the scales of billions of tons per year and ultimately about 10 billion tons per year in the year 2050."
As the Russia's invasion of Ukraine continues, medical experts are worried conditions in active warzones will exacerbate the current pandemic — or even give rise to other contagions. Dr. Daniel Fagbuyi, a war veteran and former Obama administration biodefense appointee, joined Cheddar News to discuss the ongoing danger of COVID-19 on top of the war, as well as the potential for new variants to emerge. "I mean just large volumes of people definitely is a breeding ground. That's the worst case," he said. "Two things don't mix: war-conflict and a virus, a potential pandemic virus."
Medical cannabis company Akanda went public this week in what was the first traditional IPO of the month. Shares jumped about 163% in the stock's first day of trading. The London-based company says it hopes to supply medical cannabis products to wholesalers in international markets. Tej Virk, CEO of Akanda, joins Cheddar News' Closing Bell to discuss.
